C4 Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
C4 Therapeutics, Inc. (CCCC) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$48.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-11
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$23.64M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$25.13M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$32.17M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$26.02M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$83.89M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$66.33M.
- C4 Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$34.10M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$48.76M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | -$25.13M 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | -$32.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$58.19M derived: sum of 2 quarters · filed 2026-08-11 | -$84.51M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$26.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$52.34M 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | -$26.32M 10-Q · filed 2026-05-12 | |||
| 2024-09-30 | -$24.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$42.38M derived: sum of 2 quarters · filed 2025-11-06 | -$70.74M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$17.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$46.08M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$28.36M 10-Q · filed 2025-05-07 | |||
| 2023-09-30 | -$27.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$62.96M derived: sum of 2 quarters · filed 2024-10-31 | -$97.74M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | -$35.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$70.70M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$34.78M 10-Q · filed 2024-05-08 | |||
| 2022-09-30 | -$31.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$59.37M derived: sum of 2 quarters · filed 2023-11-01 | -$90.99M 10-Q · filed 2023-11-01 | -$106.65M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$27.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$59.03M 10-Q · filed 2023-08-08 | -$74.69M derived: sum of 3 quarters · filed 2023-08-08 | -$99.37M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$31.62M 10-Q · filed 2023-05-04 | -$47.28M derived: sum of 2 quarters · filed 2023-05-04 | -$71.96M derived: sum of 3 quarters · filed 2023-05-04 | -$94.54M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$40.34M derived: sum of 2 quarters · filed 2022-11-03 | -$62.92M derived: sum of 3 quarters · filed 2022-11-03 | -$83.89M 10-K · filed 2022-02-24 |
| 2021-09-30 | -$24.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$47.26M derived: sum of 2 quarters · filed 2022-11-03 | -$68.23M 10-Q · filed 2022-11-03 | -$90.03M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$22.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$43.55M 10-Q · filed 2022-08-04 | -$65.35M derived: sum of 3 quarters · filed 2022-08-04 | -$87.18M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$20.97M 10-Q · filed 2022-05-05 | -$42.77M derived: sum of 2 quarters · filed 2022-05-05 | -$64.60M derived: sum of 3 quarters · filed 2022-05-05 | -$75.39M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$43.63M derived: sum of 2 quarters · filed 2022-02-24 | -$54.42M derived: sum of 3 quarters · filed 2022-02-24 | -$66.33M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$21.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$32.63M derived: sum of 2 quarters · filed 2021-11-10 | -$44.54M 10-Q · filed 2021-11-10 | -$54.56M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$22.70M 10-Q · filed 2021-08-11 | -$32.73M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$11.91M 10-Q · filed 2021-05-13 | -$21.93M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$34.10M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$24.08M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |